Z79.818Long term (current) use of other agents affecting estrogen receptors and estrogen levels

Z79.818 is the ICD-10-CM diagnosis code for long term (current) use of other agents affecting estrogen receptors and estrogen levels. It belongs to category Z79 (long term (current) drug therapy), block Z77-Z99 (persons with potential health hazards related to family and personal history and certain conditions influencing health status) and chapter 21 (factors influencing health status and contact with health services). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within Z79.81, choose Z79.818 (other agents affecting estrogen receptors and estrogen levels) only when documentation doesn't support a more specific option: selective estrogen receptor modulators (SERMs) (Z79.810) and aromatase inhibitors (Z79.811).

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 951 (Other Factors Influencing Health Status, relative weight 0.5577), in MDC 23 (Factors Influencing Health Status and Other Contacts with Health Services), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.

It is exempt from present-on-admission (POA) reporting, so no POA indicator is required.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as V07.59 (use of other agents affecting estrogen receptors and estrogen levels).